Misplaced Pages

Revision as of 12:08, 10 March 2016

Chemicals Start‑class Low‑importance

This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Misplaced Pages's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals Start This article has been rated as Start-class on Misplaced Pages's content assessment scale. Low This article has been rated as Low-importance on the project's importance scale.

activities

OK, let's discuss this:

It is a GABAb receptor antagonist and reversed the catatonia induced by baclofen in rats. Moreover, Homotaurine suppress ethanol-stimulated dopamine release, ethanol intake and preference in rats similar to acamprosate (Acetylated homotaurine analogue) .

References

1. Giotti A, Luzzi S, Spagnesi S, Zilletti L. "Homotaurine: a GABAB antagonist in guinea-pig ileum". PMID 6652358. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)
2. Mehta AK1, Ticku MK. "Baclofen induces catatonia in rats". PMID 2823166. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: numeric names: authors list (link)
3. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. "Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release". PMID 11864639. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)

The sources here are both old and primary. This is not how we should be sourcing WP content. These kinds of papers often turn out to be incorrect. If they are correct and valuable, they are discussed in reviews. Where are the secondary sources supporting this content? Jytdog (talk) 21:18, 9 March 2016 (UTC)

Response:

The entire document is accesible, and "it has GABAergic effects and may be useful as an anticonvulsant." has a old source too. Another source: http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=1251&AspxAutoDetectCookieSupport=1

https://books.google.es/books?id=4oXFr_aHRAwC&pg=PA169&lpg=PA169&dq=homotaurine+gabab&source=bl&ots=cvlQ4Y07ea&sig=QfMyPpg-40d1hCNINjqlHMhK7n0&hl=es&sa=X&ved=0ahUKEwjgzcyPx7TLAhXThhoKHT2jCGw4ChDoAQhLMAY#v=onepage&q=homotaurine%20gabab&f=false

http://tauruspet.med.yale.edu/staff/edm42/IUPUI-website/emorris.tar/emorris/emorris/PETjournalCLub/ideas%20for%20ntPET%20studies/Effects%20of%20acamporsate%20-%20delay%20of%20DA%20Olve%20EJPharm%202001.pdf

is 2002 an old source? OK, lets go to erase all of "old" sources. — Preceding unsigned comment added by Fonsy74 (talk • contribs) 21:36, 9 March 2016 (UTC)

this is not a response. where are the reviews discussing this? Jytdog (talk) 21:48, 9 March 2016 (UTC)

OK, I finally had time to go look for reveiws myself - here is the search. I added three reviews from that seach:

• Caltagirone C et al. The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review. Aging Clin Exp Res. 2012 Dec;24(6):580-7. PMID 22961121
• Herrmann N et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs. 2011 Oct 22;71(15):2031-65. Review. PMID 21985169
• Aisen PS Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007 Sep;4(4):473-8. PMID 17908052

None of these recent reviews mentions that GABA binding data. This appears to be not something that the field finds true or relevant - we cannot know which. This is why we rely on reviews, and not the primary literature. I have again removed this content, as MEDRS-compliant sources do not support it. Jytdog (talk) 01:16, 10 March 2016 (UTC)

Its impossible homotaurine be antagonist if it mimick gaba! Error and unsourced. Evicence says that is a gaba ionotropic agonist and gaba metrabotropic low efficacy agonist (antagonist)

Alzheimers

This content too is not appropriately sourced. moving here for now...

Homotaurine has also been investigated as a potential treatment for Alzheimer's disease. It binds to soluble amyloid beta and inhibits the formation of neurotoxic aggregates that lead to amyloid plaque deposition in the brain. However, clinical trials failed to show improvement compared to placebo.

References

1. Gauthier, S; Aisen, P. S.; Ferris, S. H.; Saumier, D; Duong, A; Haine, D; Garceau, D; Suhy, J; Oh, J; Lau, W; Sampalis, J (2009). "Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study". The journal of nutrition, health & aging. 13 (6): 550–7. PMID 19536424.
2. Aisen PS, Gauthier S, Vellas B (2007). "Alzhemed: a potential treatment for Alzheimer's disease". Curr Alzheimer Res. 4 (4): 473–8. doi:10.2174/156720507781788882. PMID 17908052. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)CS1 maint: multiple names: authors list (link)
3. "Tramiprosate Falls Short in Phase III Alzheimer's Trial". Clinical Psychiatry News. November 1, 2007.
4. "Drugs In Clinical Trials : Alzhemed". Alzheimer Research Forum. Retrieved 1 October 2011.
5. "Analysts Skeptical Of Neurochem's Efforts To Salvage Value From Alzhemed". Canada National Post. November 13, 2007. Retrieved 1 October 2011.

- Jytdog (talk) 21:19, 9 March 2016 (UTC)

You have also restored this without discussing or fixing the sources. This is not reliable content because the source are not MEDRS. Jytdog (talk) 22:18, 9 March 2016 (UTC)

I have fixed this now. Jytdog (talk) 01:16, 10 March 2016 (UTC)

• Start-Class chemicals articles
• Low-importance chemicals articles